Our comprehensive portfolio supports scientists, researchers, and institutions at the forefront of discovery with cutting-edge research tools. As trusted Partners for Life, we bring those discoveries to life with the raw materials, cell culture solutions, and services to support the manufacturing of biologics and vaccines.
We offer a diverse portfolio of advanced solutions, including specialized media, custom media development and manufacturing, and technologies for bioprocessing targeted to meet the evolving demands of the biopharmaceutical, vaccine, and cell therapy industries.
Our iPSC-derived off-the-shelf cell types (iCell® products) offer disease-relevant, human in vitro systems for drug and toxicity screening, disease modeling, and also serve as quality control and release testing platforms.
We are expanding our drug discovery contract research organization (CRO) services by utilizing cutting-edge technologies such as iPSC-derived cell assays and AIbased drug design. Specialty areas include:
- iPSC platform
- AI for drug discovery
- Infectious diseases
- Antibody discovery
- Peptide discovery
- Drug efficacy and analysis services
Our high-purity reagents play a critical role in enabling accurate, reproducible results across a wide range of applications, from molecular biology and analytical chemistry to cell culture and clinical testing.
We are your Partners for Life in bringing advanced cell therapies to patients. With end-to-end cell therapy, we provide CDMO solutions from pre-clinical development to commercial production. We offer research and manufacturing materials including iPS cell lines, cell culture solutions, reagents, cytokines, and small molecules.
- Cell therapy: We advance your cell therapies from lab to commercial scale leveraging our cell therapy expertise.
- iPS cell therapy: Our 14 fully consented, Master File enabled GMP iPSC lines can be licensed, or used in the context of our development and manufacturing services for allogeneic tissue repair approaches.
- Gene therapy: Creating effective, scalable manufacturing strategies for our partners ensures that we provide a customized service on your path to commercialization.
- Vaccines: With more than 30 years’ experience in microbial and virus-based cGMP biomanufacturing, we provide the technical expertise, process development, capacity availability, and global network that is critical for your product to reach its final delivery.
- LNP: LNP/liposome contract services support the commercialization of nanoparticle-based pharmaceuticals, leveraging our chemistry expertise
As Partners for Life, we accelerate breakthroughs in life-changing therapeutics.
Established in 2019, the Bio Science & Engineering Laboratories (BSEL) serve as an internal innovation engine that brings together employees from across Fujifilm’s businesses to continue our decades-long legacy of collaboration and innovation. This multidisciplinary hub houses more than 200 researchers — including over 50 PhD scientists and engineers — where new ideas and novel technologies are developed that strengthen Fujifilm’s scientific foundation and accelerate biomanufacturing innovation across our global network.
While many of these projects are still in early stages, they are already producing meaningful results. Examples include:
Next-generation iPS cell development: Advancing strategies for improved cell differentiation and scalability.
Single-cell RNA sequencing for T cell differentiation under GMP conditions: Enabling deeper insight into cell therapy processes for more consistent manufacturing outcomes.
Together, these efforts illustrate how BSEL bridges scientific discovery and practical implementation—driving innovation not only for Fujifilm but also for partners and customers across the full development spectrum.